Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer

Trial Identifier: D0818R00007
Sponsor: AstraZeneca
NCTID:: NCT04991051
Start Date: May 2021
Primary Completion Date: August 2022
Study Completion Date: August 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Kuwait Kuwait City, Kuwait
Oman Muscat, Oman
Qatar Doha, Qatar
Russia Arkhangelsk, Russia
Russia Belgorod, Russia
Russia Chelyabinsk, Russia
Russia Irkutsk, Russia
Russia Krasnoyarsk, Russia
Russia Moscow, Russia
Russia Nizhniy Novgorod, Russia
Russia Rostov-on-Don, Russia
Russia Saint Petersburg, Russia
Russia Tomsk, Russia
Russia Tula, Russia
Russia Tyumen, Russia
Russia Ufa, Russia
Russia Yaroslavl, Russia
Russia Yuzhno-Sakhalinsk, Russia
Russia, Moscow region Balashikha, Moscow region, Russia
Russia, Moscow region Istra settlement, Moscow region, Russia
Russia, Moscow region Kolomna, Moscow region, Russia
Saudi Arabia Jeddah, Saudi Arabia
Saudi Arabia Makka, Saudi Arabia
United Arab Emirates Alain, United Arab Emirates